References
- Van Putten T. Why do schizophrenic patients refuse to take their drugs?. Arch Gen Psychiatry 1974; 31: 67–72
- Van Putten T. The many faces of akathisia. Compr Psychiatry 1975; 6: 43–7
- Drake RE, Erlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985; 142: 499–501
- Shear MK, Frances AK, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment. Suicide 1983; 3: 235–6
- Cem Atbaoglu E, Schultz SK, Andreasen NC. The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. J Neuropsychiatry Clin Neurosci 2001; 13: 336–41
- Sachdev P. Research diagnostic criteria for drug-induced akathisia: Conceptualization, rationale and proposal. Psychopharmacology 1994; 114: 181–6
- Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. Br Med J 2000; 321: 1371–6
- Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications. Drugs 2004; 64: 701–23
- Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 2000; 20: 699–702
- Lipinski JF, Gopinath M, Zimmermann P, Pope HG. Fluoxetine-induced akathisia: Clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42
- Bazire S. Psychotropic drug directory /04. Fivepin Publishing, Salisbury, Wilts 2003
- Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663–7
- Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6
- Sachdev P. The epidemiology of drug-induced akathisia: Part 1. Acute akathisia. Schizophr Bull 1995; 21: 431–49
- Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004; 161: 160–3
- Syvälahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, Dahl ML, Salokangas RK. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997; 25: 24–32
- Lee MS, Kim YK, Lee SK, Suh KY. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 1998; 18: 399–403
- Tuisku K, Lauerma H, Holi M, Markkula J, Rimon R. Measuring neuroleptic-induced akathisia by three-channel actometry. Schizophr Res 1999; 40: 105–10
- Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003; 361: 15581–9
- Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A. Treatment of neuroleptic-induced akathisia with the 5HT2 antagonist mianserin. Double blind, placebo-controlled study. Br J Psychiatry 1999; 174: 238–42
- Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: A double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 2003; 23: 305–8